ArticleOncoimmunology2021
Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition.
Article in Oncoimmunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Intramuscular plasmid DNA electroporation sequesters neoantigen-specific CD8Molecular therapy. Oncology · 2026Article
- Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic.Journal for immunotherapy of cancer · 2026Article
- Disrupting PDGFRA-driven immune evasion in glioma: vaccine-based strategies on the horizon.Frontiers in oncology · 2026Review
- Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy.International journal of molecular sciences · 2025Review
- Review
- Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy.Cell reports. Medicine · 2024Review
- Intratumor microbiome: selective colonization in the tumor microenvironment and a vital regulator of tumor biology.MedComm · 2023Review
- Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms.Vaccines · 2023Article
- Review
- DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model.Vaccines · 2022Article
- Review
- Linear DNA amplicons as a novel cancer vaccine strategy.Journal of experimental & clinical cancer research : CR · 2022Article
- Neoantigen cancer vaccine augments anti-CTLA-4 efficacy.NPJ vaccines · 2022Article
- Engineering neoantigen vaccines to improve cancer personalized immunotherapy.International journal of biological sciences · 2022Review
- Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications.Frontiers in immunology · 2022Review
- Therapeutic cancer vaccines revamping: technology advancements and pitfalls.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a heterogeneous disease and its treatment remains unsatisfactory with inconstant therapeutic responses. This variability could be related, at least in part, to different and highly personalized gut microbiota compositions. Different studies have shown an impact of microbiota on antitumor therapy. It has been demonstrated that some gut bacteria influences the development and differentiation of immune cells, suggesting that different microbiota compositions could affect the efficacy of the antitumor vaccine. Emerging data suggest that recognition of neoantigens for the generation of neoantigen cancer vaccines (NCVs) could have a key role in the activity of clinical immunotherapies. However, it is still unknown whether there is a crosstalk between microbiota and NCV. This study aimed to understand the possible mechanisms of interaction between gut microbiota and NCV delivered by DNA-electroporation (DNA-EP). We found that decreased microbiota diversity induced by prolonged antibiotic (ATB) treatment is associated with higher intratumor specific immune responses and consequently to a better antitumor effect induced by NCV delivered by DNA-EP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.